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Dementia is the most frequent age-related neurocognitive disorder.
The health care burden and socioeconomic costs of dementia continue
to rise with aging population and increased longevity. Behavioral and
psychological symptoms of dementia (BPSD), such as excitement,
aggression, hallucinations, insomnia, anxiety, wandering, and depres-
sion, are observed in 20%–80% patients with dementia (Lawlor, 2004;
Cerejeira et al., 2012). In addition, symptom severity is positively asso-
ciated with care burden (Nagaratnam et al., 1998; Tanji et al., 2005).
Typical and atypical antipsychotics have been used for the treatment
of BPSD. However, these drugs induce extrapyramidal symptoms and
other adverse events, and as a consequence, they decrease the quality
of life and increase the difﬁculty of maintaining activities of daily living
(ADL). In 2005, the United States Food and Drug Administration (FDA)
warned that patients with dementia-related psychosis treated with
atypical antipsychotic drugs are at an increased risk of premature
death (FDA, 2005). In addition, conventional antipsychotics are also
reported to have the same risk as the atypical antipsychotics (Wang
et al., 2005). In 2008, the FDA further warned that both conventional
and atypical antipsychotics are associated with an increased risk of
mortality in elderly patients treated for dementia-related psychosis
(FDA, 2008). Since then, new remedies without adverse effects have
been sought.
In such situation, Iwasaki et al. (2005) reported that yokukansan
(YKS), a traditional JapaneseKampomedicine, whichhad been originat-
ed from the traditional Chinese medicine Yi-Gan-San, improved such
excitatory BPSD as hallucinations, agitation, and aggressiveness in 52
patients with Alzheimer's disease (AD), dementia with Lewy bodies
(DLB), and other forms of senile dementia, identifying YKS as a new
potential therapeutic agent for BPSD. Subsequent clinical trials veriﬁed
the efﬁcacy of YKS in patients with dementia. For instance, Mizukami
et al. (2009) evaluated the efﬁcacy and safety of YKS in 106 patients
diagnosed with AD or DLB in a randomized cross-over study and
found that YKS was an effective and well-tolerated treatment for
patients with BPSD without serious adverse reactions. Monji et al.
(2009) demonstrated that YKS was beneﬁcial for treatment of BPSD in
15 elderly patients with AD and suggested that it could also reduce
the dose of antipsychotics required for BPSD treatment. Similarly,
Okahara et al. (2010) reported high efﬁcacy and safety of YKS in a
non-blinded, randomized, parallel-group comparison study of 63
patients with AD. Furthermore, Matsuda et al. (2013) performed a
meta-analysis of four randomized controlled trials of YKS for BPSD
including 236 patients with dementia (Iwasaki et al., 2005; Mizukami
et al., 2009; Monji et al., 2009; Okahara et al., 2010) and concluded
that YKS was well tolerated with beneﬁcial effects on neuropsychiatric
inventory and ADL scores. In addition to patients with AD (Okahara
et al., 2010; Hayashi et al., 2010) and DLB (Iwasaki et al., 2012), YKS
has been reported to be effective for BPSD such as agitation and
disinhibition in patients with vascular dementia without adverse
effects (Nagata et al., 2012). These ﬁndings suggest that YKS may
improve BPSD regardless of dementia type. YKS has also been shown
effective for the symptomatic treatment of other neuropsychiatric
disorders, like borderline personality disorder (Miyaoka et al., 2008a),
neuroleptic-induced tardive dyskinesia (Miyaoka et al., 2008b),
treatment-resistant schizophrenia (Miyaoka et al., 2009), pervasive
developmental disorder not otherwise speciﬁed (PDD-NOS), Asperger's
disorder (Miyaoka et al., 2012), postoperative delirium (Saito et al.,
2010), preoperative anxiety (Arai et al., 2014), neuropathic pain
(Nakamura et al., 2009), and urticaria/itching (Kato et al., 2010).
In parallel with such clinical investigations, preclinical basic studies
have progressed rapidly to clarify the bioactive ingredients and
mechanisms of YKS. Kampo medicine is the extract of multiple crude
drugs containing a large number of ingredients. Although thismolecular
complexity is a major impediment to research the therapeutic
mechanisms of Kampo medicine, it is an advantage for variouspharmacological effects. YKS is composed of seven dried crude drugs,
and three-dimensional high-performance liquid chromatographic
analysis has identiﬁed a plethora of chemical ingredients (Mizukami
et al., 2009; Nagata et al., 2012; Tsuji et al., 2014). To date, over 70
basic research articles have been published on the pharmacological
efﬁcacy and mechanisms of YKS, its constituent herbs, and ingredients,
and the pharmacokinetics, metabolism, and brain distribution of active
ingredients. In this review, we describe the neuropharmacology of YKS,
focusing on these basic studies.
2. Yokukansan (YKS)
YKS originally appeared as Yi-Gan San in the “Bâo yïng cuö yào”, the
Synopsis for Protecting Infant written by Xue Kai during the Ming
dynasty (1555) in China as a remedy for restlessness and agitation in
children. It was introduced to Japan in the late 17th century, and a
formula for use in adults was developed in the late 18th century. At
present, YKS is in widespread use as a traditional herbal medicine,
which has approved by the Japanese Ministry of Health, Labor and
Welfare as a remedy for neurosis, insomnia, and irritability and night
crying in children. It is composed of seven dried medicinal herbs,
Atractylodes lancea rhizome (4.0 g, rhizome of Atractylodes lancea De
Candolle), Poria sclerotium (4.0 g, sclerotium of Poria cocos Wolf),
Cnidium rhizome (3.0 g, rhizome of Cnidium ofﬁcinaleMakino), Uncaria
hook (3.0 g, thorn of Uncaria rhynchophyllaMiquel), Japanese Angelica
root (3.0 g, root of Angelica acutiloba Kitagawa), Bupleurum root
(2.0 g, root of Bupleurum falcatum Linné), and Glycyrrhiza (1.5 g, root
and stolon of Glycyrrhiza uralensis Fisher). Each plant material is identi-
ﬁed by its external morphology and authenticated by marker com-
pounds of plant specimens according to the methods of the Japanese
Pharmacopoeia and our company's standard. To produce the dried
YKS extract powder, themixture of seven component herbs is extracted
with puriﬁed hotwater at 95 °C for 1 h. The extract solution is separated
from the insoluble waste and spray-dry to produce the dried extract
powder. The quality is standardized based onGoodManufacturing Prac-
tice deﬁned by the Ministry of Health, Labour and Welfare of Japan. As
shown in Fig. 1, we have identiﬁed at least 25 ingredients in the meth-
anol fraction of YKS extract by three-dimensional high-performance
liquid chromatographic analysis with ultraviolet detection (Mizukami
et al., 2009; Nagata et al., 2012; Tsuji et al., 2014).
3. Neuropharmacological actions
Several reports have shown the neuropharmacological actions of
YKS, which include the effects on serotonergic, glutamatergic, choliner-
gic, dopaminergic, adrenergic, and gamma-aminobutyric acid
(GABA)ergic neural systems, as well as neuroprotective effect, anti-
stress effect, promotion of neuroplasticity, and anti-inﬂammatory effect.
These are thought to be associatedwith the therapeutic efﬁcacies of YKS
on BPSD (Fig. 2).
3.1. Serotonergic neurotransmission
3.1.1. Serotonin 1A (5-HT1A) receptor
As described, YKS ameliorated positive BPSD-like aggressiveness in
clinical trials (Iwasaki et al., 2012; Matsuda et al., 2013). In animals,
aggressive behaviors are related to dysfunction of the cerebral
serotonergic system (Nichols, 2004). In fact, we demonstrated a
signiﬁcant increase in aggressive behavior and decrease in social
behavior in cerebral 5-HT-deﬁcient rats treated with the 5-HT neuro-
toxin ρ-chloroamphetamine (Kanno et al., 2009). YKS ameliorated this
neurotoxin-induced aggressive behavior and impaired social behavior
as effectively as the 5-HT1A receptor partial agonist buspirone and the
5-HT2A receptor antagonist ketanserin. From this result, we speculated
tentatively that the ameliorative effects of YKS may be due to agonism
of the 5-HT1A receptor or antagonism of the 5-HT2A receptor.
Fig. 1.Three-dimensional chromatogramof YKS extract. The dried extract (1 g) of YKSwasdissolved in 20ml ofmethanol under ultrasonication for 30min and centrifuged at 3000 rpm for
5min. The supernatantwas ﬁltrated through a 0.45 μmmembrane ﬁlter. A 30 μl sample of theﬁltratewas injected into a high-performance liquid chromatography systemwith ultraviolet
detection.
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tive binding assay for 5-HT receptors in membranes of Chinese
hamster ovary cell stably expressing human recombinant 5-HT1A or
5-HT2A receptors (Terawaki et al., 2010). YKS competitively inhibited
[3H](±)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-
DPAT) binding to the 5-HT1A receptor but not [3H]ketanseri binding
to 5-HT2A receptor. The [35S]GTPγS binding assay showed that YKS
had a partial agonistic effect on the 5-HT1A receptor, as the maximal
[35S]GTPγS binding rate in the presence of YKS was approximately
50% of that of a full agonist 5-HT. Similar binding characteristics
were found only for Uncaria hook among the seven constituent
herbs of YKS. Furthermore, the binding characteristics of YKS to the
5-HT1A receptor were markedly attenuated by eliminating Uncaria
hook from YKS but were almost unchanged when other
components were individually eliminated. A subsequent in vitro bind-
ing assay to identify the active ingredients from Uncaria hook showed
that only geissoschizine methyl ether (GM) among seven alkaloidsFig. 2. Neuropharmacological actions of YKS. 5-HT, serotonergic neurotransmission;
Glu, glutamatergic neurotransmission; ACh, cholinergic neurotransmission; DA,
dopaminergic neurotransmission; NE/E, adrenergic neurotransmission; GABA,
GABAergic neurotransmission, Protect: Neuroprotection; “Others” include anti-stress,
neuroplasticity, neurogenesis, and anti-inﬂammation.strongly bound to the 5-HT1A receptor and acted as a partial agonist
with efﬁcacy similar to YKS and Uncaria hook (Nishi et al., 2012).
We next aimed to verify these in vitro results by examining the
efﬁcacy of Uncaria hook for ameliorating aggression and reduced social
behaviors in socially isolated mice (Nishi et al., 2012). The mitigating
effect of YKS (1.0 g/kg) was completely abolished by removal of Uncaria
hook, and oral administration of 150 mg/kg Uncaria hook, the
equivalent amount in 1.0 g/kg YKS, also signiﬁcantly reduced aggression
and promoted social behaviors as effectively as YKS. Further, oral
administration of 150 μg/kg GM, the equivalent amount in 1.0 g/kg
YKS, also ameliorated aggressiveness and reduced sociality as effectively
as YKS and Uncaria hook. These effects of YKS, Uncaria hook, and GM
were counteracted by co-administration of the 5-HT1A receptor antago-
nist WAY-100635. These results suggest that GM in Uncaria hook is a
potent 5-HT1A receptor agonist and a candidate bioactive agent
mediating the effects of YKS on aggression and reduced sociality
induced by social isolation. Other in vivo studies also reported that
WAY-100635 counteracted the ameliorative effects of YKS against
aggressive behavior, reduced social behavior, and anxiety observed
in various animal models (Kanno et al., 2009; Nishi et al., 2012;
Yamaguchi et al., 2012).
Interestingly, Ueki et al. (2015a) demonstrated that YKS increased
the density of 5-HT1A receptor in the prefrontal cortex (PFC) of socially
isolatedmice and also enhanced the behavioral response (i.e., decreased
rearing behavior) induced by the 5-HT1A receptor agonist 8-OH-DPAT,
suggesting that YKS increases 5-HT1A receptor expression and function-
al activity. Considering that GM behaves as a partial agonist for 5-HT1A
receptors, YKS is suggested to have structure in its formula to enhance
the effects of GM by upregulating 5-HT1A receptor expression.
3.1.2. Serotonin 2A (5-HT2A) receptor and other subtype receptors
Egashira et al. (2008) reported that oral administration of YKS
to normal mice ameliorated the 5-HT2A receptor agonist 2,5-
dimethoxy-4-iodoamphetamine (DOI)-induced head-twitch response
(a hallucination-like behavior in mice) by downregulating 5-HT2A
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recently, we demonstrated that YKS reduced the enhancedDOI-induced
head-twitch response in isolation-stressedmice and downregulated the
increased 5-HT2A receptor density in the PFC of these stressed mice
(Ueki et al., 2015b); in this study, the downregulation of 5-HT2A
receptors is suggested to be induced by a synergistic effect of
Bupleurum root, Uncaria hook, Japanese Angelica root, and Glycyrrhiza
among the seven constituent components of YKS. Thus, the ameliorative
effect of YKS on hallucination-like behaviors may result from 5-HT2A
receptor downregulation by multiple YKS components, although the
exact mechanisms are currently unclear. Carrasco et al. (2007) and
Wieland et al. (1993) demonstrated that activation of 5-HT1A receptors
desensitizes 5-HT2A receptors, suggesting that YKS may induce 5-HT2A
receptor downregulation through partial agonistic action on 5-HT1A
receptors.
Ueda et al. (2011) reported in a single-cell-based Ca2+ imaging
assay that GM, which is a candidate for pharmacological effect of YKS,
has third-generation antipsychotic-like actions at the 5-HT andFig. 3. Chemical structures of (A) Uncaria hook-derived indole alkaloids (geissoschizine
isorhynchophylline, corynoxeine, isocorynoxeine), and ﬂavonoid (procyanidin B1), and (B)
ﬂavonoids (liquiritin apioside, liquiritin, liquiritigenin, isoliquiritin, isoliquiritigenin, and glycycdopamine (DA) receptors, i.e., GM behaves as a partial agonist at the
5-HT1A receptor, an antagonist at the 5-HT2A, 5-HT2C, and 5-HT7
receptors, and a partial agonist/antagonist at the D2L receptor, like
aripiprazole. Ueki et al. (2013) also reported that GM has an antagonis-
tic effect on the 5-HT7 receptor as determined by measuring intracellu-
lar cAMP levels in HEK293 cells stably expressing human recombinant
5-HT7 receptor. With regard to the 5-HT2A receptor, although we
could not detect the 5-HT2A antagonist effect in experiments using
YKS extract, GM had measurable 5-HT2A antagonist activity. This may
be due to the differences in crude extract YKS and single-ingredient
GM. As described in detail below, the evidence that GM is detected in
the blood and brain of rats orally administered YKS (Imamura et al.,
2011) suggests that YKS hasmultiple actions on 5-HT receptors through
GM.
In addition to GM, Uncaria hook contains other indole alkaloids
such as hirsuteine and hirsutine, as well as oxindole alkaloids like
rhynchophylline, isorhynchophylline, corynoxeine, and isocorynoxeine
(Fig. 3). These oxindole alkaloids have a carbonyl group at the C2methyl ether (GM), hirsuteine, and hirsutine), oxindole alkaloids (rhynchophylline,
Glycyrrhiza-derived triterpenoids (glycyrrhizin and 18β-glycyrrhetinic acid (GA)) and
oumarin).
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and showed no binding activity to 5-HT1A and 5-HT7 receptors. Alterna-
tively, GM showed strong binding activity for these receptors, while
hirsuteine, which has very similar structure to GM, did not bind to
them. As shown in Fig. 3, the conformations at C3 and the side chain
at C20 (GM has a double bond at C19–20 and hirsuteine at C18–19) dif-
fer and the resulting steric change may relate to 5-HT1A or 5-HT7 recep-
tor binding activity.
3.1.3. Serotonin (5-HT) release
Mizoguchi et al. (2010) reported that YKS reversed the decreased 5-
HT release in the PFC of aged rats, which might be associated with the




Zinc deﬁciency has been shown to increase glutamate concentra-
tion in the brain tissue of mice and extracellular glutamate concen-
tration in the hippocampus of rats (Takeda et al., 2008a; Tamano
et al., 2010). Moreover, social isolation in zinc-deﬁcient mice in-
duced aggressive behavior. YKS ameliorated this aggressive behavior
and normalized the concomitant increased glutamate concentra-
tions (Takeda et al., 2008a; Tamano et al., 2010; Takeda et al.,
2012). This normalization of glutamate concentrations is due to inhi-
bition of excess glutamate release via reduced exocytosis in the hip-
pocampus (Takeda et al., 2008b). More recently, Tamano et al.
(2016) suggested that GM and 18β-glycyrrhetinic acid (GA), a
major metabolite of glycyrrhizin contained in Glycyrrhiza, amelio-
rated excess glutamate release from mossy ﬁber boutons by sup-
pressing the increase in intracellular Ca2+ signaling.
3.2.2. Glutamate transport
We demonstrated that thiamine deﬁciency inducedmemory distur-
bances and BPSD-like symptoms including anxiety, aggressive behavior,
and reduced social behavior in rats (Ikarashi et al., 2009; Iizuka et al.,
2010). Electronmicroscopy of the brain showedmore severe degenera-
tion of astrocytes than neurons in several brain regions, including brain
stem, hippocampus, and cerebral cortex. Amicrodialysis study revealed
elevated extracellular glutamate in the thiamine-deﬁcient brain. YKS
prevented the development of memory disturbances and BPSD-like
behaviors, astrocyte degeneration, and increased brain glutamate level
resulting from thiamine deﬁciency. Considering that astrocytes have a
role in removal of excessive extracellular glutamate, these observations
suggest that thiamine deﬁciency enhances extracellular glutamate
by reducing astroglial-mediated uptake via glutamate transporters,
and YKS prevents these dysfunctions. Indeed, YKS ameliorated the
thiamine deﬁciency-induced decrease in both glutamate uptake into
in cultured rat astrocytes and the concomitant reduction in expression
of glutamate–aspartate transporter (GLAST) mRNA and protein
(Kawakami et al., 2009). Moreover, the ameliorative effect of YKS
against reduced glutamate transport was completely abolished by the
glutamate transporter inhibitor DL-threo-β-hydroxy-aspartic acid.
Taken together, these results strongly suggest that YKS protects astro-
cytes from damage induced by thiamine deﬁciency, thereby preserving
glutamate transporter function.
Among the seven constituent herbs of YKS, a signiﬁcant promotion
of glutamate transport was found for Glycyrrhiza. Furthermore, we
found that glycyrrhizin and GA among eight ingredients (Fig. 3) of
Glycyrrhiza ameliorated the thiamine deﬁciency-induced decrease in
cultured astroglial glutamate uptake in a concentration-dependent
manner (Kawakami et al., 2009, 2010). Glutamate transporter expres-
sion and glutamate transport activity are decreased by protein kinase
C (PKC)-activating phorbol esters (Conradt & Stoffel, 1997; Gonzalez
et al., 1999), and these ingredients inhibited PKC activity. In addition,both reductions of glutamate uptake and glutamate transporter protein
expression in astrocytes under thiamine deﬁciency were reversed by
treatment with the PKC inhibitor H-7 (Hazell et al., 2003). These lines
of evidence suggest that glycyrrhizin and GA are likely responsible for
the ameliorative effects of YKS on dysfunction of glutamate transport
in astrocytes by inhibiting PKC.
Glutamate-related mechanisms of YKS have been reported
in other animal models. In rats exhibiting haloperidol-induced
tardive dyskinesia, YKS ameliorated the associated increase in striatal
extracellular glutamate by increasing the expression of glutamate
transporter mRNA (Sekiguchi et al., 2012). In the rat chronic constric-
tion injury model of neuropathic pain, YKS inhibited the brush-
and acetone-induced increase in cerebrospinal ﬂuid glutamate
concentration, and these anti-allodynia actions were counteracted by
intrathecal injection of the nonspeciﬁc glutamate transporter-1 (GLT-
1) and GLAST inhibitor DL-threo-β-hydroxy-aspartic acid and by the
selective GLT-1 inhibitor dihydrokainate (Suzuki et al., 2012). Facilitat-
ing actions of GA on glutamate uptake may be involved in these effects
of YKS.
Control of glutamate, the predominant fast excitatory neurotrans-
mitter in the brain, is also critical for inhibition of neurotoxicity
(excitotoxicity), and YKS has neuroprotective effects. These are
described in the section of neuroprotection below.
3.3. Cholinergic neurotransmission
In vitro biochemical assays showed that YKS did not affect
acetylcholinesterase and choline acetyltransferase activities or bind to
cholinoreceptors and choline transporter (Sekiguchi et al., 2011). How-
ever, hippocampal acetylcholine release was increased by YKS treat-
ment in rats subjected to cerebrovascular ischemia (Nogami et al.,
2013) and amyloid β (Aβ) protein intracerebroventricular injection
plus ischemia/reperfusion injury (Uchida et al., 2013). These authors
suggested that the acetylcholine-releasing effects of YKS are related to
an increase in dynamin 1, which is known to play a critical role in syn-
aptic vesicle recycling, and are associated with amelioration of learning
and memory dysfunction. There are several studies that have demon-
strated the usefulness of other Kampo medicines (chotosan and
tokishakuyakusan) in the treatment of cognitive disorders. As these
medicines contain constituent herbs that are similar to those (Uncaria
hook in chotosan, and Atractylodes lancea rhizome, Poria sclerotium,
Cnidium rhizome, Japanese Angelica root in tokishakuyakusan) in YKS,
they (Uchida et al., 2013) are inferring that the overlapped constituents
may be active components. Unfortunately, the active ingredients re-
sponsible for the expression of dynamin 1 remain unknown.
3.4. Dopaminergic neurotransmission
Although GM behaves as a partial agonist/antagonist at the D2L
receptor (Ueda et al. 2011), an in vitro competitive binding assay
showed that YKS itself did not affect the binding of DA receptor
subtype-speciﬁc radioligands (Sekiguchi et al., 2012). Extrapyramidal
symptoms such as inhibition of motor activity and catalepsy, which
are induced by a DA deﬁcit or DA receptor blockade, were not observed
in various animal models treated with YKS (Sekiguchi et al., 2009;
Kanno et al., 2009; Nishi et al., 2012). Mizoguchi et al. (2010) reported
that YKS improved the age-related decrease in dopaminergic transmis-
sion (as evidenced by increased extracellular concentrations) in the PFC,
which might be associated with the ameliorative effects of YKS on age-
related cognitive impairments (Mizoguchi et al., 2011). More recently,
Ishida et al. (2016) reported that YKS facilitated DA supplementation
by L-DOPA via catechol-O-methyltransferase inhibition in ratswith uni-
lateral 6-hydroxydopamine lesions in the nigrostriatal dopaminergic
pathway. They suggested that the Uncaria hook alkaloids GM and
corynoxeine may contribute these effects of YKS.
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Action of YKS on adrenergic neurotransmission has been studied
only in the context of morphine dependence in mice (Nakagawa
et al., 2012). YKS signiﬁcantly attenuated morphine tolerance and
naloxone-precipitated morphine withdrawal signs (jumps and body
weight loss) without affecting the analgesic effect of morphine. The
inhibitory effect of YKS on morphine withdrawal jumps was blocked
by a single pretreatment with the α2-adrenoceptor antagonist
yohimbine but not by the α1-adrenoceptor antagonist prazosin. A sim-
ilar inhibitory effect on withdrawal jumps was observed by repeated
administration of yohimbine. Plasma membrane α2A-adrenoceptor
expression in the pons–medulla was reduced during morphine with-
drawal, and this reduction was prevented by repeated administration
of YKS or yohimbine. An in vitro receptor binding assay demonstrated
that YKS and two of its constituent herbs, Uncaria hook andGlycyrrhiza,
revealed an antagonistic effect for α2A adrenoceptor and that certain
chemical ingredients, includingGM, glycyrrhizin, andGA shared this ac-
tivity. Furthermore, administration of Uncaria hook, Glycyrrhiza, or
their respective ingredients (GM or glycyrrhizin) signiﬁcantly inhibited
morphine withdrawal signs. These results suggest that GM and
glycyrrhizin in YKS inhibit morphine tolerance and physical depen-
dence by blocking α2A-adrenoceptors, thereby preventing decreased
receptor expression in the brainstem.
3.6. GABAergic neurotransmission
YKS has been reported to reverse the shortening of pentobarbital-
induced sleep time in socially isolated mice (Egashira et al., 2011).
This effect is thought to involve the GABAA-benzodiazepine receptor
complex but not 5-HT1A receptors because reversal was blocked by
the GABAA receptor antagonist bicuculline and the selective benzodiaz-
epine receptor antagonist ﬂumazenil but not by the selective 5-HT1A
receptor antagonist WAY 100635. Kamei et al. (2009) suggested that
the anxiolytic-like effect of YKS may be mediated by GABAA receptor
stimulation and that the effective ingredients are contained in the
water-soluble fraction of YKS. Liao et al. (1995) reported that the
water extract of Japanese Angelica root, a constituent herb of YKS,
bound toGABAA receptors in vitro. However, we have found that YKS in-
cludes water-soluble botanic GABA (Nishi et al., 2012). When we
completely washed out the GABA contained in YKS using distilled
water and then obtained the methanol extract, an in vitro binding
assay showed no binding to either the GABA or benzodiazepine binding
site. These results suggest that the binding of YKS against GABAA/benzo-
diazepine receptor is due to botanic GABA in YKS because the active in-
gredients were not included in the methanol extract. However, orally
administrated GABA does not pass efﬁciently across the blood–brain
barrier (BBB) (Cooper et al., 1991). Therefore, we suggest that YKS
does not directly act on GABAA/benzodiazepine receptors in the brain.
Rather, the effects of YKS on the receptors may be indirect, for example,
allopregnanolone, a potent positive allosteric modulator of GABA
actions at the GABAA receptor, may be involved in the effects of YKS
(Matsumoto et al., 1999).
3.7. Neuroprotection
3.7.1. Glutamate neurotoxicity
Glutamate is the major fast excitatory neurotransmitter in the
central nervous system, and synaptic plasticity at glutamatergic
synapses is essential for certain forms of learning andmemory. Howev-
er, high extracellular glutamate concentrations or prolonged elevation
induces excitotoxic neuronal death (Choi, 1988; Cheung et al., 1998).
As already described, YKS mitigates the disruption of astroglial gluta-
mate transport, thereby preventing excitotoxicity. In addition, YKS has
been demonstrated to have a direct protective effect on neurons
(Kawakami et al., 2011a); YKS (100 μg/mL) protected primary culturedrat cortical neurons against 100 μM glutamate-induced neuronal death.
Among the seven constituent herbs of YKS, highest potency of protec-
tion was found for Uncaria hook and Glycyrrhiza, suggesting that
these herbs contain neuroprotective ingredients. Fig. 3 shows the ingre-
dients examined for neuroprotective efﬁcacy. Four ingredients in
Uncaria hook (10 μM GM, hirsuteine, hirsutine, and rhynchophylline)
and four ingredients in Glycyrrhiza (10 μM glycycoumarin,
isoliquiritigenin, liquiritin, and glycyrrhizin) showed neuroprotective
efﬁcacy, suggesting that individual ingredients additively and/or syner-
gistically contribute to the neuroprotective effect of YKS. In N-methyl-
D-aspaetate (NMDA) receptor binding and receptor-linked Ca2+ inﬂux
assays, only isoliquiritigenin bound to and antagonizedNMDAreceptors
and inhibited glutamate-induced Ca2+ inﬂux. However, the neuropro-
tective effect of isoliquiritigeninmight not bemediated byNMDArecep-
tor antagonismbecause the concentration needed for substantial NMDA
binding (N100 μM) and inhibition of Ca2+-inﬂux (300 μM)were higher
than that for its neuroprotective effect (10 μM). These ﬁndings sug-
gested that it was difﬁcult to explain the neuroprotective effect of YKS
by NMDA receptor antagonismof isoliquiritigenin and thatmechanisms
other than NMDA receptor antagonismmust account for the neuropro-
tective efﬁcacy of YKS.
3.7.2. Antioxidant effect of yokukansan (YKS)
mediated by the cysteine/glutamate antiporter system Xc−
Regarding glutamate neurotoxicity, two mechanisms have been
proposed; glutamate receptor-mediated neurotoxicity and cystine/glu-
tamate antiporter system Xc− inhibition-mediated neurotoxicity (Choi,
1988; Murphy et al., 1990; Schubert et al., 1992; Froissard & Duval,
1994; Pereira & Oliveira, 2000; Penugonda et al., 2005; Edwards et al.,
2007; Lo et al., 2008). The system Xc− imports the amino acid cystine,
an oxidized form of cysteine, into cells with 1:1 counter-transport of
glutamate. It consists of two protein components, the 4F2 heavy chain
necessary for membrane localization of the heterodimer and the xCT
protein responsible for transporter activity. Cysteine is the rate-
limiting substrate for synthesis of the antioxidant glutathione (GSH),
along with cystine (Lo et al., 2008; Conrad & Sato, 2012; Lewerenz
et al., 2012, 2013). PC12 cells express the system Xc− but not a normal
NMDA receptor subunit proﬁle (Pereira & Oliveira, 2000; Penugonda
et al., 2005; Edwards et al., 2007; Lo et al., 2008; Vazhappilly et al.,
2010). Furthermore, glutamate-induced cell death in PC12 cells was
not blocked by 100 μM MK-801, which is sufﬁcient to block
glutamate-induced neuronal death (Lysko et al., 1989). Conversely,
100 μM NMDA, which is sufﬁcient to induce neuronal death (Zhu
et al., 2003), did not induce cell death in PC12 cells. Previous reports
have shown that PC12 cells do not express functional NMDA receptors
(Kawakami et al., 2011b). These ﬁndings suggest that PC12 cell death
induced by glutamate is not due to stimulation of NMDA receptors
and that the PC12 cell is a valuablemodel to selectively evaluate the im-
proving effects on glutamate-mediated cytotoxicity through system
Xc− inhibition. We found that YKS had cytoprotective effect against
glutamate-mediated cytotoxicity in PC12 cells (Kawakami et al.,
2011b; Kanno et al., 2014). When the effects of the seven constituent
herbs in YKS on PC12 cell death were examined separately, Uncaria
hook was found to have the highest cytoprotective potency, and the
Uncaria hook ingredients GM, hirsutine, hirsuteine, and procyanidin
B1 all had cytoprotective effects. These ingredients enhanced gene
expression of system Xc− subunits xCT and 4F2 heavy chain and ame-
liorated the glutamate-induced decrease in the antioxidant GSH levels.
The cytoprotective effects of YKS and these four Uncaria hook-derived
ingredients were counteracted by co-treatment with the system Xc−
inhibitor (S)-4-carboxyphenylglycine. These results suggest that the en-
hancement of system Xc− gene expression by these four ingredients
may contribute, at least in part, to the cytoprotective efﬁcacy of YKS
by preserving cellular antioxidant capacity (GSH cycling). A similar
protective effect of YKS against GSH reduction was observed in the
brain of mice treated with polyinosinic–polycytidilic acid (Makinodan
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induced neurotoxicity in cultured cells through suppressing reactive ox-
ygen species generation and upregulating glycolysis (Sun et al., 2016).
3.7.3. Amyloid β (Aβ) neurotoxicity
In the brains of patients with AD, Aβ aggregates and forms insoluble
ﬁbrils that are the major component of senile plaques. Recently, Aβ
oligomers have been focused as a mechanism of the pathology for AD
because of its neurotoxicity both in vivo and in vitro. YKS has been
demonstrated to suppress Aβ oligomer-induced neuronal apoptosis in
primary cultured cortical neurons (Tateno et al., 2008; Kanno et al.,
2013). Moreover, we found that glycycoumarin in Glycyrrhiza and
procyanidin B1 in Uncaria hook contribute to the neuroprotective effect
of YKS through the suppression of the apoptosis effector caspase-3
(Kanno et al., 2015).
With regard to Aβ aggregation, Fujiwara et al. (2006) reported that
Uncaria hook has a potent anti-aggregation effect on Aβ proteins
in vitro. Tabuchi et al. (2009) examined the effects of YKS on Aβ accu-
mulation in the brain of amyloid precursor protein-transgenic mice,
and showed that YKS did not inhibit histological deposition of Aβ and
production of soluble and insoluble forms of Aβ. On the other hand,
Fujiwara et al. (2011) showed that YKS and Uncaria hook prevented
the accumulation of cerebral Aβ in the same animal model. At present,
the in vivo effects of YKS against Aβ deposition have been controversial,
but both studies demonstrated that YKSpreventedmemory disturbance
and aggressive behavior. These preventative effects of YKS may be
mediated by the mechanisms related to neuroprotection and neuro-
transmission rather than anti-Aβ aggregation effects, and this may be
attributed to Uncaria hook.
3.7.4. 1-Methyl-4-phenylpyridine (MPP+)/
1-methyl-4-phenyl1,2,3,6-tetrahydropyridene (MPTP) neurotoxicity
Doo et al. (2010) investigated the neuroprotective effects of YKS
against MPP+/MPTP-induced cytotoxicity in vitro and in vivo. Pre-
treatment of SH-SY5Y human neuroblastoma cells with YKS
protected against MPP+-induced cell death and signiﬁcantly de-
creased caspase-3 activity concomitant with increased expression
of phospho-activated Akt (protein kinase B). An inhibitor of
phosphatidyl-inositol 3-kinase (PI3K), LY294002, signiﬁcantly
decreased this protective effect of YKS. In mice, YKS treatment also
signiﬁcantly improved motor dysfunction and prevented dopami-
nergic neuronal loss related to MPTP challenge, a model of
Parkinson's disease. These results suggest that YKS can rescue dopa-
minergic neurons from MPP+/MPTP toxicity via activation of the
PI3K/Akt signaling pathway. Recently, Kubota et al. (2013) demon-
strated in PC12 cells that YKS induced nerve growth factor-like phos-
phorylation and activation of protein kinase and lipid kinase
pathways, including extracellular signal-regulated kinase 1/2 and
PI3K/Akt pathways known to regulate neuronal protection, prolifer-
ation, and differentiation (Vaudry et al., 2002; Chen et al., 2012), as
well as neurite outgrowth (Tsuji et al., 2001). β-Eudesmol, a
sesquiterpenoid isolated from Atractylodes lancea rhizome, is sug-
gested to be one of candidates for neurotrophic effects (Obara
et al., 2002; Kubota et al., 2013).
3.7.5. Endoplasmic reticulum (ER) stress
ER stress is known to activate two pathways; survival and apoptotic
pathways. The survival pathway involves the increased transcription of
genes encoding ER stress-resident chaperones, including glucose-
regulated protein/binding immunoglobulin protein (GRP78/Bip),
GRP94, and protein disulﬁde isomerase, which facilitate protein folding
(Kozutsumi et al., 1988; Sidrauski et al., 1998; Tirasophon et al., 1998;
Oyadomari et al., 2002), while the apoptotic pathway involves the
induction of C/EBP homologous protein (CHOP), also known as growth
arrest and DNA damage-inducible gene153 (GADD153) (Oyadomari
et al., 2002; Oyadomari & Mori, 2004). YKS prevented the death ofSK–N–SH human neuroblastoma cells and neuro-2a mouse neuroblas-
toma cells resulting from ER stress induced by hypoxic exposure or
thapsigargin (Hiratsuka et al., 2010). It was suggested that these
protective effects are mediated by both upregulation of GRP78/Bip ex-
pression and inhibition of CHOP induction. In addition, YKS and
Cnidium rhizome inhibited caspase-4 activation under ER stress. Ferulic
acid contained in Cnidium rhizomewas suggested to play an important
role in this protective effect of YKS.
3.8. Anti-stress effect
Severe and accumulative stress is thought to participate or
exacerbate anxiety, depression, and cognitive deﬁcits in humans and
animals (Anisman & Zacharko, 1990; Mazure, 1995; Mizoguchi et al.,
2000). Stress activates the hypothalamic–pituitary–adrenal axis,
resulting in the release of glucocorticoid hormones that enhance
adaptive capacity to stress (Sapolsky et al., 1986; Porter et al., 2001).
However, excessive glucocorticoids are considered to be cytotoxic to
neurons. As described above, repeated administration of YKS attenuated
stress-induced neuronal excitation in the rat PFC and amygdala as
measured by c-Fos expression (Shoji & Mizoguchi, 2013). Nakatani
et al. (2014) also reported that YKS protected corticosterone-induced
neurotoxicity in mouse primary cultured hippocampal neurons. More
recently, Shimizu et al. (2015a,b) demonstrated that YKS normalized
the stress-induced elevation of plasma corticosterone, possibly through
a microRNA-dependent mechanism. MicroRNAs are noncoding RNAs
that inhibit the translation and/or decrease the stability of their target
mRNAs, ultimately decreasing target protein expression (Carthew,
2006; Wang et al., 2007). MicroRNA-18 and/or 124a are candidate
negative regulators of glucocorticoid receptor (GR) expression in the
brain (Vreugdenhil et al., 2009), and enhanced GR signaling attenuates
the hypothalamic–pituitary–adrenal axis activity. In mice, YKS reversed
the stress-induced decrease in GR proteins in the paraventricular
nucleus of the hypothalamus and oligodendrocytes of the corpus
callosum. YKS also decreased microRNA-18 in the paraventricular
nucleus and microRNA-124a in callosal oligodendrocytes, although GR
mRNA level was not signiﬁcantly changed in either region (Shimizu
et al., 2015a,b). These results suggest that YKS normalizes the stress-
induced decrease in GR proteins by downregulating microRNA-18 and
124a expression levels and subsequently disinhibiting GR mRNA
translation.
3.9. Neuroplasticity, neurogenesis, proliferation, and differentiation
Extracellular matrix-associated glycoproteins such as chondroitin
sulfate proteoglycans regulate the proliferation, migration, and neurite
outgrowth of neural stem cells in the brain and act to maintain the
structure and function of adult neurons. Tanaka & Mizoguchi (2009)
examined the inﬂuence of aging and the improving effects of YKS on
the expression of aggrecan, a major chondroitin sulfate proteoglycan,
on the proliferation and migration of neural stem/progenitor cells
identiﬁed by bromodeoxyuridine (BrdU) incorporation in the PFC and
hippocampus/dentate gyrus of aged rats. In the aged rat PFC and hippo-
campus, increased aggrecan expression and decreased numbers of
BrdU-labeled cells were observed, and these changes were reversed
by YKS treatment. These results suggest that aging inﬂuences the
microenvironment for adult and immature neurons in the brain,
which may affect the proliferation and migration of neural stem/pro-
genitor cells, while YKS induces growth-permissive changes in the
brainmicroenvironment. This enhanced neurogenesis was also demon-
strated in the dentate gyrus of YKS-treated Gunn rats (Furuya et al.,
2013). In addition, YKS promoted neurite outgrowth in PC12 cells
through activation of extracellular signal-regulated kinase (Erk)1/2
and PI3K/Akt as described above (Kubota et al., 2013).
YKS also promoted the proliferation of puriﬁed mouse cortical ol-
igodendrocyte precursor cells and their differentiation into
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for this effect (Ueki et al., 2014). This result was supported by Morita
et al. (2014), who examined the effect of GM on demyelination in
cuprizone-treated mice, and demonstrated that GM signiﬁcantly in-
creased BrdU-labeled GSTpi+ mature oligodendrocytes and attenuated
the decrease in myelin basic protein immunoreactivity in the medial
PFC. From these results, they suggested that GM may enhance both
proliferation of oligodendrocyte precursor cells and their differentiation
into oligodendrocytes.
3.10. Anti-inﬂammatory effect
Liu et al. (2014) examined the anti-inﬂammatory and antioxidant
properties of YKS in gerbils subjected to cerebral ischemia/reperfusion
injury. YKS attenuated the injury-induced inﬂammatory response (the
increased number of Iba1 immunoreactive microglia), DNA oxidative
damage (a high level of 8-hydroxy-2′-deoxyguanisine) and subsequent
neuronal apoptosis in the hippocampal CA1 area. Furuya et al. (2013)
demonstrated that YKS attenuated microglial activation as evaluated
by enhanced CD11b immunoreactivity in Iba1-labeled cells, and
promoted neurogenesis in the hippocampal dentate gyrus of Gunn
rats. In addition, several ingredients in YKS possess potential anti-
inﬂammatory property; rhynchophylline and isorhynchophylline in
Uncaria hook (Yuan et al., 2009; Song et al., 2012), GA and liquiritigenin
in Glycyrrhiza (Khaksa et al., 1996; Kim et al., 2008), saikosaponin a, c, d,
e in Bupleurum root (Lu et al., 2012), β-eudesmol in Atractylodes lancea
rhizome (Seo et al., 2011), senkyunolide A, Z-ligustilide, and ferulic acid
in Cnidium rhizome (Cheng et al., 2008; Or et al., 2011), pachymic acid
in Poria scletotium (Nukaya et al., 1996). Taken together, these ﬁndings
suggest that the pharmacological activity of YKS may be mediated in
part by an anti-inﬂammatory effect.
4. Pharmacokinetics
4.1. Detection of geissoschizine methyl ether (GM) and 18β-glycyrrhetinic
acid (GA) in the plasma and brain, and blood–brain barrier permeabilities
We have describedmultiple psychotropic effects of YKS and constit-
uent components and their pharmacological mechanisms. While it is
possible that many active ingredients remain to be identiﬁed, several
lines of evidence suggest that GM and GA are major contributors to
the pharmacologic efﬁcacy of YKS. Subsequent pharmacokinetics
studies demonstrated that GM and GA were detected in the plasma of
rats orally administered YKS (0.5–4.0 g/kg). The maximum concentra-
tion (Cmax) of GM reached 8.46 ± 1.38 ng/ml in rats administered
4.0 g/kg YKS while the Cmax of GA was 839 ± 112 ng/ml after adminis-
tration of 1.0 g/kg YKS. The time tomaximumdrug concentration (tmax)
was 1.2 ± 0.6 h for GM and 8.7 ± 0.7 h for GA, at which time both
ingredients were detected in the brain (Imamura et al., 2011; Tabuchi
et al., 2012; Kushida et al., 2013). In vitro BBB permeability studies
using co-cultured primary rat brain endothelial cells, pericytes, and as-
trocytes indicated that GM and GA are able to cross brain endothelial
cells (Imamura et al., 2011; Tabuchi et al., 2012). Considering that
most glycyrrhizin (a glycoside of GA) is metabolized to GA in the
intestine by bacterial ﬂora, after which GA is absorbed into the blood
(Akao et al., 1994; Takeda et al., 1996; Ploeger et al., 2001), these results
suggest that GM is absorbed directly into theblood or glycyrrhizin is as a
metabolite GA, and then reaches the brain through the BBB. More
recently, almost equivalent data were obtained in the plasma of healthy
Japanese volunteers orally administered YKS in a cross-over, random-
ized study (Kitagawa et al., 2015). These results are consistent with a
previous ﬁnding that GAwas detectable in the plasma after glycyrrhizin
or Glycyrrhiza was orally administered to rats (Wang et al., 1994) and
human (Cantelli-Forti et al., 1994).
GM absorbed into the plasma from the intestine is rapidly eliminat-
ed with a half-life (t1/2) of 1.7 h. Studies using recombinant humancytochrome P450 (CYP) isoforms and human liver microsomes suggest
that GM is metabolized into hydroxylated, dehydrogenated, hydroxyl-
ated plus dehydrogenated, demethylated, and water adduct forms by
CYP isoforms (Kushida et al., 2015; Matsumoto et al., 2016). Among
these CYP isoforms, CYP3A4 has been found to mainly contribute to
GM metabolism. On the other hand, GA exhibits substantially longer
tmax (8 h) and t1/2 (11 h) values than GM. Glycyrrhizin, an ingredient
of Glycyrrhiza, was poorly absorbable and not detected in plasma.
Glycyrrhizin is mainly absorbed as its active metabolite GA after
presystemic hydrolysis by intestinal bacterial ﬂora in the gastrointesti-
nal tract. GA absorbed into the blood is taken up into the liver by
capacity-limited carriers, and metabolized into glucuronide and sulfate
conjugates. These conjugates are transported efﬁciently into the bile.
After outﬂow of the bile into the duodenum, the conjugates are hydro-
lyzed back to GA by commensal bacteria, which are subsequently
reabsorbed, causing a pronounced delay to reach the terminal plasma
concentration (Ploeger et al., 2001).
Thus, YKS is a mixture of components, some with relatively short
half-lives (1.7 h) and other with relatively long half-lives (11 h). In ad-
dition, pharmacokinetic evidence, including measurements of GM and
GA in the plasma and brain and of their BBB permeability, supports
the possibility that these are the active ingredients conferring the
psychotropic effects of YKS.4.2. Distribution of geissoschizine methyl ether
(GM) and 18β-glycyrrhetinic acid (GA) in the brain
In rats, both GM and GA do reach the brain by crossing the BBB
following oral YKS administration. Then, to identify and characterize
the binding sites of GM and GA in the brain, autoradiography using
tritium-labeled GM ([3H]GM) or GA ([3H]GA) was performed in rat
brain sections (Mizoguchi et al., 2014a,b). Speciﬁc binding of [3H]GM
was observed in the frontal cortex, including the PFC (e.g., prelimbic
cortex), hippocampus, caudate putamen, amygdala, central medial
thalamic nucleus, and dorsal raphe nucleus, regions related to various
psychiatric symptoms and critical for learning and memory functions.
Speciﬁc binding with relatively high afﬁnity was dense in the frontal
cortical region, moderate in the dorsal raphe nucleus, and sparse in
the cerebellum. The speciﬁc binding of [3H]GM was signiﬁcantly
inhibited by the 5-HT1A receptor agonist 8-OH-DPAT, 5-HT2A receptor
antagonist ketanserin, 5-HT2B receptor agonist BW723C86, 5-HT2C
receptor agonist RO60–0175, adrenergic α2A receptor antagonist
yohimbine, L-type Ca2+ channel blocker verapamil, and μ-opioid recep-
tor antagonist naloxone in the prelimbic cortex, frontal cortex, and
dorsal raphe nucleus. Microautoradiography revealed that [3H]GM
signals were distributed throughout the frontal cortex, in which
neuron-like large cells were included. These results demonstrate that
speciﬁc binding sites for GM exist in rat brain and suggest that the phar-
macological actions of GM are associated mainly with 5-HT receptors in
the frontal cortex and dorsal raphe nucleus (Mizoguchi et al., 2014b)
(Fig. 4).
Speciﬁc binding of [3H]GA was highest in the hippocampus,
moderate in the caudate putamen, nucleus accumbens, amygdala,
olfactory bulb, cerebral cortex, thalamus, and mid brain, and lower
in the brain stem and cerebellum. Several steroids, gap junction-
blocking reagents, glutamate transporter-recognizing compounds,
and glutamate receptor agonists did not inhibit [3H]GA binding.
Microautoradiography showed that [3H]GA signals in the hippocampus
were distributed in small non-neuronal cells resembling astrocytes. Im-
munohistochemical analysis revealed that immunoreactivity for 11β-
hydroxysteroid dehydrogenase type-1, a deﬁned molecule recognized
by GA (Irie et al., 1992), was detected intensely in neurons, moderately
in astrocytes, and very slightly in microglial cells of the hippocampus.
These results demonstrate that speciﬁc binding sites for GA exist in rat
brain and suggest that the pharmacological actions of GAmaybe related
Fig. 4. Possible mechanisms underlying the neuropharmacological efﬁcacy of YKS through GM and GA. After oral YKS administration, glycyrrhizin (GL) is metabolized to GA by intestinal
ﬂora. Then, unmetabolized GM and GA are absorbed into blood, and reach the brain by crossing the BBB. In the brain, it is possible that GM predominantly binds 5-HT1A receptors in the
frontal cortex as the partial agonist, whichmediates anti-aggressive and anxiolytic effects, and GA distributes to astrocytes in the hippocampus, which reduces excessive glutamate (Glu)
and inhibits excitation.
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et al., 2014a) (Fig. 4).
5. Conclusion
Aging is one of the contemporary social issues, and dementia is one
of the typical diseases associatedwith age. In Japan, the current number
of patients with dementia has exceeded 460million people. That is, one
in four people older than 65 years of age has some form of dementia or
mild cognitive impairment. Cognitive deﬁcits and BPSD are typical fea-
tures of AD, DLB, vascular dementia, and other forms of senile dementia.
Clinical studies have demonstrated that YKS ameliorates various BPSD,
including agitation/aggression, irritability, hallucinations, anxiety,
sleep disturbance, and aberrant motor activity, as well as other symp-
toms including pain and itching.
In this review, we focused on evidence obtained from preclinical
basic studies demonstrating the neuropharmacological efﬁcacy of YKS,
its bioactive ingredients, and pharmacokinetics. As concluded in Fig. 2,
YKS had multiple neuropharmacological actions. Studies to identify
the active ingredient suggested that alkaloids in Uncaria hook and
triterpenes and ﬂavonoids in Glycyrrhiza were major contributors to
the neuropharmacological actions of YKS (Fig. 3). Among them, it was
found that GM and GA are particularly important bioactive ingredients
in the serotonergic and glutamatergic mechanisms, respectively.
Referring the pharmacokinetic ﬁndings, these ingredients reached the
brain, in which GM might ameliorate aggressiveness and anxiety
through partial agonistic actions for 5-HT1A receptors in the frontal
cortex and GA might reduce excessive glutamate by acting glutamate
transporters in astrocytes (Fig. 4).
Nonetheless, YKS is composed of seven dried medicinal herbs
containing a myriad of chemical ingredients. Although speculative, the
formula of YKSmight be modiﬁed to express multiple neuropharmaco-
logical actions that are integrated to treat neurosis and insomniawithout severe side effects, thereby maximizing the clinical beneﬁts.
Generally, traditional herbal medicines are a mixture of several crude
drugs and consist of a large number of components or ingredients,
which may systemically control a complex network system formed by
numerous biomolecules. Such medicines are accordance with a theory
of multicomponent drugs (Kitano, 2007), and the broad efﬁcacy of
YKS is consistent with this theory. In addition, traditional herbal medi-
cines could be considered as a ‘long-tail’ drug because many of the
ingredients are thought to be on the long tail of a statistical distribution
in the formula (Kitano, 2007). Although we identiﬁed GM and GA as
main contributors for the psychotropic actions of YKS, the intrinsic
beneﬁts of YKS are probably attributable to the complex activities of
the whole formula rather than individual components or ingredients.
This idea is supported by the ﬁnding that the United States National
Cancer Institute identiﬁed only 3 effective drugs in 35,000 samples of
roots and fruits from 12,000 plant species (Yuan & Lin, 2000), suggest-
ing that additive and/or synergistic effects of multiple components
may be associated with pharmacological actions of natural plants,
including Kampo medicine. The information described in this review
could facilitate to understand the pharmacology of multicomponent
drugs, and may also be available to develop therapeutic drugs for
dementia based on a systems-oriented drug design approach (Kitano,
2007).
More recently, the safety and frequency of adverse drug reactions in
3156 patients treated with YKS were investigated for up to 52 weeks
(Hisada et al., 2014). Adverse drug reactions occurred in 136 cases
(4.3%) after the administration of YKS. Major adverse drug reactions
were metabolism and nutrition disorders, with hypokalemia being the
main symptom (1.4%), general disorder and administration site condi-
tion (1.0%), and gastrointestinal disorder with diarrhea and nausea as
the chief symptoms (0.6%). Although these incidences are relatively
low, since YKS contains Glycyrrhiza, hypokalemia should be closely
monitored. For more widespread clinical application of YKS, it is
93Y. Ikarashi, K. Mizoguchi / Pharmacology & Therapeutics 166 (2016) 84–95necessary to accumulate more safety information and side effect pro-
ﬁles in addition to further evidence on the effectiveness, molecular
mechanisms of bioactive ingredients, and their interaction.
Conﬂict of interest statement
The authors are employees of Tsumura & Co. The authors declare
that, except for income received from the employer, no ﬁnancial
support or compensation has been received from any individual or
corporate entity and no conﬂict of interest exists.
Acknowledgments
For studies conducted at Tsumura Research Laboratories, the authors
thank the following researchers and managers for planning the studies,
performing the experiments, analyzing the data, writing the papers, and
for stimulating discussion: Toshiyuki Ueki, Zenji Kawakami, Masahiro
Tabuchi, Sachiko Imamura, Akinori Nishi, Hitomi Kanno, Takuji
Yamaguchi, Kyoji Sekiguchi, Takashi Matsumoto, Hirotaka Kushida,
Junko Watanabe, Tomohisa Hattori, and Yoshio Kase.
The authors would like to thank Enago (www.enago.jp) for the
English language review.
References
Akao, T., Hayashi, T., Kobashi, K., Kanaoka, M., Kato, H., Kobayashi, M., et al. (1994).
Intestinal bacterial hydrolysis is indispensable to absorption of 18β-glycyrrhetic
acid after oral administration of glycyrrhizin in rats. J Pharm Pharmacol 46, 135–137.
Anisman, H., & Zacharko, R. M. (1990). Multiple neurochemical and behavioral
consequences of stressors: Implications for depression. Pharmacol Ther 46, 119–136.
Arai, Y. C., Kawanishi, J., Sakakima, Y., Sueoka, S., Ito, A., Tawada, Y., et al. (2014). The effect
of the Kampomedicine yokukansan on preoperative anxiety and sedation levels. Evid
Based Complement Alternat Med 2014, 965045.
Cantelli-Forti, G., Maffei, F., Hrelia, P., Bugamelli, F., Bernardi, M., D'Intino, P., et al. (1994).
Interaction of licorice on glycyrrhizin pharmacokinetics. Environ Health Perspect 102,
65–68.
Carrasco, G. A., Van de Kar, L. D., Jia, C., Xu, H., Chen, Z., Chadda, R., et al. (2007). Single
exposure to a serotonin 1A receptor agonist, (+)8-hydroxy-2-(di-n-propylamino)-
tetralin, produces a prolonged heterologous desensitization of serotonin 2A receptors
in neuroendocrine neurons in vivo. J Pharmacol Exp Ther 320, 1078–1086.
Carthew, R. W. (2006). Gene regulation by microRNAs. Curr Opin Genet Dev 16, 203–208.
Cerejeira, J., Lagarto, L., & Mukaetova-Ladinska, E. B. (2012). Behavioral and psychological
symptoms of dementia. Front Neurol 3, 73.
Chen, J. Y., Lin, J. R., Cimprich, K. A., & Meyer, T. (2012). A two-dimensional ERK-AKT
signaling code for an NGF-triggered cell-fate decision. Mol Cell 45, 196–209.
Cheng, C. Y., Ho, T. Y., Lee, E. J., Su, S. Y., Tang, N. Y., & Hsieh, C. L. (2008). Ferulic acid re-
duces cerebral infarct through its antioxidative and anti-inﬂammatory effects follow-
ing transient focal cerebral ischemia in rats. Am J Chin Med 36, 1105–1119.
Cheung, N. S., Pacoe, C. J., Giardina, S. F., John, C. A., & Beart, P. M. (1998). Micromo-
lar L-glutamate induces extensive apoptosis in an apoptotic–necrotic continu-
um of insult-dependent, excitotoxic injury in cultured cortical neurones.
Neuropharmacology 37, 1419–1429.
Choi, D. W. (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron
1, 623–634.
Conrad, M., & Sato, H. (2012). The oxidative stress-inducible cystine/glutamate antiporter,
system Xc−: cystine supplier and beyond. Amino Acids 42, 231–246.
Conradt, M., & Stoffel, W. (1997). Inhibition of the high-afﬁnity brain glutamate
transporter GLAST-1 via direct phosphorylation. J Neurochem 68, 1244–1251.
Cooper, J. R., Bloom, F. E., & Roth, R. H. (Eds.). (1991). Amino acid transmitters: The
biochemical basis of neuropharmacology (pp. 133–189). Oxford University Press.
Doo, A. R., Kim, S. N., Park, J. Y., Cho, K. H., Hong, J., Eun-Kyung, K., et al. (2010). Neuropro-
tective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxic-
ity in vitro and in vivo. J Ethnopharmacol 131, 433–442.
Edwards, M. A., Loxley, R. A., Williams, A. J., Connor, M., & Phillips, J. K. (2007). Lack of
functional expression of NMDA receptors in PC12 cells. Neurotoxicology 28, 876–885.
Egashira, N., Iwasaki, K., Ishibashi, A., Hayakawa, K., Okuno, R., Abe, M., et al. (2008). Re-
peated administration of yokukansan inhibits DOI-induced head-twitch response and
decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal
cortex. Prog Neuropsychopharmacol Biol Psychiatry 32, 1516–1520.
Egashira, N., Nogami, A., Iwasaki, K., Ishibashi, A., Uchida, N., Takasaki, K., et al. (2011).
Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: possible
involvement of GABAA-benzodiazepine receptor complex. J Pharmacol Sci 116,
316–320.
FDA (2005). FDA public health advisory: Deaths with antipsychotics in elderly
patients with behavioral disturbances. http://www.fda.gov/cder/drug/advisory/
antipsychotics.htm
FDA (2008). Information for healthcare professionals: Conventional antipsychotics.
http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm
Froissard, P., & Duval, D. (1994). Cytotoxic effects of glutamic acid on PC12 cells.
Neurochem Int 24, 485–493.Fujiwara, H., Iwasaki, K., Furukawa, K., Seki, T., He, M., Maruyama, M., et al. (2006).
Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects
on Alzheimer's beta-amyloid proteins. J Neurosci Res 84, 427–433.
Fujiwara, H., Takayama, S., Iwasaki, K., Tabuchi, M., Yamaguchi, T., Sekiguchi, K., et al.
(2011). Yokukansan, a traditional Japanese medicine, ameliorates memory distur-
bance and abnormal social interaction with anti-aggregation effect of cerebral
amyloid β proteins in amyloid precursor protein transgenic mice. Neuroscience 180,
305–313.
Furuya, M., Miyaoka, T., Tsumori, T., Liaury, K., Hashioka, S., Wake, R., et al. (2013).
Yokukansan promotes hippocampal neurogenesis associated with the suppression
of activated microglia in Gunn rat. J Neuroinﬂammation 10, 145.
Gonzalez, M. I., Lopez-Colom, A. M., & Ortega, A. (1999). Sodium-dependent glutamate
transporter in Muller glial cells: regulation by phorbol esters. Brain Res 831, 140–145.
Hayashi, Y., Ishida, Y., Inoue, T., Udagawa, M., Takeuchi, K., Yoshimuta, H., et al. (2010).
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia
with Yokukansan in clinical practice. Prog Neuropsychopharmacol Biol Psychiatry 34,
541–545.
Hazell, A. S., Pannunzio, P., Rama Rao, K. V., Pow, D. V., & Rambaldi, A. (2003). Thiamine
deﬁciency results in downregulation of the GLAST glutamate transporter in cultured
astrocytes. Glia 43, 175–184.
Hiratsuka, T., Matsuzaki, S., Miyata, S., Kinoshita, M., Kakehi, K., Nishida, S., et al. (2010).
Yokukansan inhibits neuronal death during ER stress by regulating the unfolded pro-
tein response. PLoS One 5, e13280.
Hisada, T., Maki, A., Katori, Y., & Motoki, K. (2014). Adverse drug reaction frequency
investigation of Tsumura yokukansan extract granules for ethical use. Diagn Treat
102, 1577–1589.
Iizuka, S., Kawakami, Z., Imamura, S., Yamaguchi, T., Sekiguchi, K., Kanno, H., et al. (2010).
Electron-microscopic examination of effects of yokukansan, a traditional Japanese
medicine, on degeneration of cerebral cells in thiamine-deﬁcient rats.
Neuropathology 30, 524–536.
Ikarashi, Y., Iizuka, S., Imamura, S., Yamaguchi, T., Sekiguchi, K., Kanno, H., et al. (2009).
Effects of yokukansan, a traditional Japanese medicine, on memory disturbance and
behavioral and psychological symptoms of dementia in thiamine-deﬁcient rats. Biol
Pharm Bull 32, 1701–1709.
Imamura, S., Tabuchi, M., Kushida, H., Nishi, A., Kanno, H., Yamaguchi, T., et al. (2011). The
blood–brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a
galenical constituent of the traditional Japanese medicine yokukansan. Cell Mol
Neurobiol 31, 787–793.
Irie, A., Fukui, T., Negishi, M., Nagata, N., & Ichikawa, A. (1992). Glycyrrhetinic acid bound
to 11 beta-hydroxysteroid dehydrogenase in rat liver microsomes. Biochim Biophys
Acta 1160, 229–234.
Ishida, Y., Ebihara, K., Tabuchi, M., Imamura, S., Sekiguchi, K., Mizoguchi, K., et al. (2016).
Yokukansan, a traditional Japanesemedicine, enhances the L-DOPA induced rotation-
al response in 6-hydroxydopamine-lesioned rats: possible inhibition of COMT. Biol
Pharm Bull 39, 104–113.
Iwasaki, K., Kosaka, K., Mori, H., Okitsu, R., Furukawa, K., Manabe, Y., et al. (2012). Im-
provement in delusions and hallucinations in patients with dementiawith Lewy bod-
ies upon administration of yokukansan, a traditional Japanese medicine.
Psychogeriatrics 12, 235–241.
Iwasaki, K., Satoh-Nakagawa, T., Maruyama, M., Monma, M. N., Nemoto, M., Tomita, N.,
et al. (2005). A randomized, observer-blind, controlled trial of the traditional Chinese
medicine Yi-Gan San for improvement of behavioral and psychological symptoms
and activities of daily living in dementia patients. J Clin Psychiatry 66, 248–252.
Kamei, J., Miyata, S., & Ohsawa, M. (2009). Involvement of the benzodiazepine system in
the anxiolytic-like effect of yokukansan (Yi-gan san). Prog Neuropsychopharmacol Biol
Psychiatry 33, 1431–1437.
Kanno, H., Kawakami, Z., Iizuka, S., Tabuchi, M., Mizoguchi, K., Ikarashi, Y., et al. (2013).
Glycyrrhiza and Uncaria hook contribute to protective effect of traditional Japanese
medicine yokukansan against amyloid β oligomer-induced neuronal death. J
Ethnopharmacol 149, 360–370.
Kanno, H., Kawakami, Z., Mizoguchi, K., Ikarashi, Y., & Kase, Y. (2014). Yokukansan, a
kampo medicine, protects PC12 cells from glutamate-induced death by augmenting
gene expression of cystine/glutamate antiporter system Xc−. PLoS One 2014,
e116275.
Kanno, H., Kawakami, Z., Tabuchi, M., Mizoguchi, K., Ikarashi, Y., & Kase, Y. (2015). Protec-
tive effects of glycycoumarin and procyanidin B1, active components of traditional
Japanese medicine yokukansan, on amyloid β oligomer-induced neuronal death. J
Ethnopharmacol 159, 122–128.
Kanno, H., Sekiguchi, K., Yamaguchi, T., Terawaki, K., Yuzurihara, M., Kase, Y., et al. (2009).
Effect of yokukansan, a traditional Japanese medicine, on social and aggressive be-
haviour of para-chloroamphetamine-injected rats. J Pharm Pharmacol 61, 1249–1256.
Kato, S., Kato, T. A., Nishie, H., Nishima, S., Iwanaga, T., Monji, A., et al. (2010). Successful
treatment of chronic urticaria with a Japanese herbal medicine, yokukansan. J
Dermatol 37, 1066–1067.
Kawakami, Z., Ikarashi, Y., & Kase, Y. (2011a). Isoliquiritigenin is a novel NMDA receptor
antagonist in Kampo medicine yokukansan. Cell Mol Neurobiol 31, 1203–1212.
Kawakami, Z., Kanno, H., Ikarashi, Y., & Kase, Y. (2011b). Yokukansan, a kampo medicine,
protects against glutamate cytotoxicity due to oxidative stress in PC12 cells. J
Ethnopharmacol 134, 74–81.
Kawakami, Z., Ikarashi, Y., & Kase, Y. (2010). Glycyrrhizin and its metabolite 18β-
glycyrrhetinic acid in Glycyrrhiza, a constituent herb of yokukansan, ameliorate thia-
mine deﬁciency-induced dysfunction of glutamate transport in cultured rat cortical
astrocytes. Eur J Pharmacol 626, 154–158.
Kawakami, Z., Kanno, H., Ueki, T., Terawaki, K., Tabuchi, M., Ikarashi, Y., et al. (2009). Neu-
roprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-
mediated excitotoxicity in cultured cells. Neuroscience 159, 1397–1407.
Khaksa, G., Zolfaghari, M. E., Dehpour, A. R., & Samadian, T. (1996). Anti-inﬂammatory and
anti-nociceptive activity of disodium glycyrrhetinic acid hemiphthalate. Planta Med
62, 326–328.
Kim, Y. W., Zhao, R. J., Park, S. J., Lee, J. R., Cho, I. J., Yang, C. H., et al. (2008).
Antiinﬂammatory effects of liquiritigenin as a consequence of the inhibition of NF-
94 Y. Ikarashi, K. Mizoguchi / Pharmacology & Therapeutics 166 (2016) 84–95kappaB-dependent iNOS and proinﬂammatory cytokines production. Br J Pharmacol
154, 165–173.
Kitagawa, H., Munekage, M., Ichikawa, K., Fukudome, I., Munekage, E., Takezaki, Y., et al.
(2015). Pharmacokinetics of active components of yokukansan, a traditional
Japanese herbal medicine after a single oral administration to healthy Japanese
volunteers: A cross-over, randomized study. PLoS One 10, e0131165.
Kitano, H. (2007). A robustness-based approach to systems-oriented drug design. Nat Rev
Drug Discov 6, 202–210.
Kozutsumi, Y., Segal, M., Normington, K., Gething, M. J., & Sambrook, J. F. (1988). The
presence of malfolded proteins in the endoplasmic reticulum signals the induction
of glucose-regulated proteins. Nature 332, 462–464.
Kubota, K., Sano, K., Shiraishi, A., Beppu, N., Nogami, A., Uchida, N., et al. (2013).
Yokukansan, a traditional Japanese herbal medicine, promotes neurite outgrowth in
PC12 cells through the activation of extracellular signal regulated kinase 1/2 and
phosphatidylinositol 3-kinase/Akt. J Trad Med 30, 102–113.
Kushida, H., Fukutake, M., Tabuchi, M., Katsuhara, T., Nishimura, H., Ikarashi, Y., et al.
(2013). Simultaneous quantitative analyses of indole and oxindole alkaloids of
Uncaria hook in rat plasema and brain after oral administration of the traditional
Japanese medicine yokukansan using high-performance liquid chromatography
with tandem mass spectrometry. Biomed Chromatogr 27, 2647–2656.
Kushida, H., Matsumoto, T., Igarashi, Y., Nishimura, H., Watanabe, J., Maemura, K., et al.
(2015). Metabolic proﬁling of the Uncaria hook alkaloid geissoschizine methyl
ether in rat and human liver microsomes using high-performance liquid chromatog-
raphy with tandem mass spectrometry. Molecules 20, 2100–2114.
Lawlor, B. A. (2004). Behavioral and psychological symptoms in dementia: The role of
atypical antipsychotics. J Clin Psychiatry 65(Suppl. 11), 5–10.
Lewerenz, J., Hewett, S. J., Huang, Y., Lambros, M., Gout, P. W., Kalivas, P. W., et al. (2013).
The cystine/glutamate antiporter system Xc− in health and disease: from molecular
mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 18, 522–555.
Lewerenz, J., Maher, P., & Methner, A. (2012). Regulation of xCT expression and system
Xc− function in neuronal cells. Amino Acids 42, 171–179.
Liao, J. F., Jan, Y. M., Huang, S. Y., Wang, H. H., Yu, L. L., & Chen, C. F. (1995). Evaluation with
receptor binding assay on the water extracts of ten CNS-active Chinese herbal drugs.
Proc Natl Sci Counc Repub China B 19, 151–158.
Lo, M., Wang, Y. Z., & Gout, P. W. (2008). The Xc− cystine/glutamate antiporter: a poten-
tial target for therapy of cancer and other diseases. J Cell Physiol 215, 593–602.
Liu, Y., Nakamura, T., Toyoshima, T., Lu, F., Sumitani, K., Shinomiya, A., et al. (2014). Ame-
liorative effects of yokukansan on behavioral deﬁcits in a gerbil model of global cere-
bral ischemia. Brain Res 1543, 300–307.
Lu, C. N., Yuan, Z. G., Zhang, X. L., Yan, R., Zhao, Y. Q., Liao, M., et al. (2012). Saikosaponin a
and its epimer saikosaponin d exhibit anti-inﬂammatory activity by suppressing
activation of NF-kappaB signaling pathway. Int Immunopharmacol 14, 121–126.
Lysko, P. G., Cox, J. A., Vigano, M. A., & Henneberry, R. C. (1989). Excitatory amino acid
neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: Pharmaco-
logical characterization. Brain Res 499, 258–266.
Makinodan, M., Yamauchi, T., Tatsumi, K., Okuda, H., Noriyama, Y., Sadamatsu, M., et al.
(2009). Yi-Gan San restores behavioral alterations and a decrease of brain glutathione
level in a mouse model of schizophrenia. J Brain Dis 1, 1–6.
Matsuda, Y., Kishi, T., Shibayama, H., & Iwata, N. (2013). Yokukansan in the treatment
of behavioral and psychological symptoms of dementia: A systematic review and
meta-analysis of randomized controlled trials. Hum Psychopharmacol 28, 80–86.
Matsumoto, T., Kushida, H., Maruyama, T., Nishimura, H., Watanabe, J., Maemura, K., et al.
(2016). In vitro identiﬁcation of human cytochrome P450 isoforms involved in the
metabolism of Geissoschizine methyl ether, an active component of the traditional
Japanese medicine yokukansan. Xenobiotica 46, 325–334.
Matsumoto, K., Uzunova, V., Pinna, G., Taki, K., Uzunov, D. P., Watanabe, H., et al. (1999).
Permissive role of brain allopregnanolone content in the regulation of pentobarbital-
induced righting reﬂex loss. Neuropharmacology 38, 955–963.
Mazure, C. M. (1995). Does stress cause psychiatric illness? In D. Spiegel (Ed.), Progress in
psychiatry (pp. 270–298). Washington, DC: American Psychiatric.
Miyaoka, T., Furuya, M., Yasusda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008a). Yi-
gan san for the treatment of borderline personality disorder: An open-label study.
Prog Neuropsychopharmacol Biol Psychiatry 32, 150–164.
Miyaoka, T., Furuya, M., Yasusda, H., Hayashida, M., Nishida, A., Inagaki, T., et al. (2008b).
Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: An open-
label study. Prog Neuropsychopharmacol Biol Psychiatry 32, 761–764.
Miyaoka, T., Furuya, M., Yasusda, H., Hayashida, M., Nishida, A., Inagaki, T., et al. (2009).
Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: An open-
label study. Clin Neuropharmacol 32, 6–9.
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., et al. (2012).
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not
otherwise speciﬁed and Asperger's disorder: A 12-week prospective, open-label
study. BMC Psychiatry 12, 215.
Mizoguchi, K., Kanno, H., Ikarashi, Y., & Kase, Y. (2014a). Speciﬁc binding and characteris-
tics of 18β-glycyrrhetinic acid in rat brain. PLoS One 9, e95760.
Mizoguchi, K., Kushida, H., Kanno, H., Igarashi, Y., Nishimura, H., Ikarashi, Y., et al. (2014b).
Speciﬁc binding and characteristics of Geissoschizine methy ether, an indole alkaloid
of Uncaria hook, in rat brain. J Ethnopharmacol 158, 264–270.
Mizoguchi, K., Shoji, H., Tanaka, Y., & Tabira, T. (2011). Ameliorative effect of traditional
Japanese medicine yokukansan on age-related impairments of working memory
and reversal learning in rats. Neuroscience 177, 127–137.
Mizoguchi, K., Tanaka, Y., & Tabira, T. (2010). Anxiolytic effect of a herbal medicine,
yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmis-
sion in the prefrontal cortex. J Ethnopharmacol 127, 70–76.
Mizoguchi, K., Yuzurihara, M., Ishige, A., Sasaki, H., Chui, D. H., & Tabira, T. (2000). Chronic
stress induces impairment of spatial working memory because of prefrontal dopami-
nergic dysfunction. J Neurosci 20, 1568–1574.
Mizukami, K., Asada, T., Kinoshita, T., Tanaka, K., Sonohara, K., Nakai, R., et al. (2009). A
randomized cross-over study of a traditional Japanese medicine (kampo),
yokukansan, in the treatment of the behavioural and psychological symptoms of
dementia. Int J Neuropsychopharmacol 12, 191–199.Monji, A., Takita, M., Samejima, T., Takaishi, T., Hashimoto, K., Matsunaga, H., et al. (2009).
Effect of yokukansan on the behavioral and psychological symptoms of dementia in
elderly patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol
Psychiatry 33, 308–311.
Morita, S., Tatsumi, K., Makinodan, M., Okuda, H., Kishimoto, T., & Wanaka, A. (2014).
Geissoschizine methyl ether, an alkaloid from the Uncaria hook, improves
remyelination after cuprizone-induced demyelination in medial prefrontal cortex of
adult mice. Neurochem Res 39, 59–67.
Murphy, T. H., Schnaar, R. L., & Coyle, J. T. (1990). Immature cortical neurons are uniquely
sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4, 1624–1633.
Nagaratnam, N., Lewis-Jones, M., Scott, D., & Palazzi, L. (1998). Behavioral and psychiatric
manifestations in dementia patients in a community: Caregiver burden and outcome.
Alzheimer Dis Assoc Disord 12, 330–334.
Nagata, K., Yokoyama, E., Yamazaki, T., Takano, D., Maeda, T., Takahashi, S., et al. (2012).
Effects of yokukansan on behavioral and psychological symptoms of vascular demen-
tia: An open-label trial. Phytomedicine 19, 524–528.
Nakagawa, T., Nagayasu, K., Nishitani, N., Shirakawa, H., Sekiguchi, K., Ikarashi, Y., et al.
(2012). Yokukansan inhibits morphine tolerance and physical dependence in mice:
The role of α2A-adrenoceptor. Neuroscience 227, 336–349.
Nakamura, Y., Tajima, K., Kanai, M., & Mitsuhata, H. (2009). Efﬁcacy of traditional herbal
medicine, yokukansan on patients with neuropathic pain. Masui 10, 1248–1255.
Nakatani, Y., Tsuji, M., Amano, T., Miyagawa, K., Miyagishi, H., Saito, A., et al. (2014). Neu-
roprotective effect of yokukansan against cytotoxicity induced by corticosterone on
mouse hippocampal neurons. Phytomedicine 21, 1458–1465.
Nichols, D. E. (2004). Hallucinogens. Pharmacol Ther 101, 131–181.
Nishi, A., Yamaguchi, T., Sekiguchi, K., Imamura, S., Tabuchi, M., Kanno, H., et al. (2012).
Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin1A re-
ceptor agonist and candidate for amelioration of aggressiveness and sociality by
yokukansan. Neuroscience 207, 124–136.
Nogami, A., Takasaki, K., Kubota, K., Yamaguchi, K., Kawasaki, C., Nakamura, K., et al.
(2013). Effect of yokukansan on memory disturbance in an animal model of cerebro-
vascular dementia. J Trad Med 30, 164–175.
Nukaya, H., Yamashiro, H., Fukazawa, H., Ishida, H., & Tsuji, K. (1996). Isolation of inhibi-
tors of TPA-induced mouse ear edema from Hoelen, Poria cocos. Chem Pharm
Bull(Tokyo) 44, 847–849.
Obara, Y., Aoki, T., Kusano, M., & Ohizumi, Y. (2002). β-Eudesmol induces neurite
outgrowth in rat pheochromocytoma cells accompanied by an activation of
mitogen-activated protein kinase. J Pharmacol Exp Ther 301, 803–811.
Okahara, K., Ishida, Y., Hayashi, Y., Inoue, T., Tsuruta, K., Takeuchi, K., et al. (2010). Effects
of yokukansan on behavioral and psychological symptoms of dementia in regular
treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 34,
532–536.
Or, T. C., Yang, C. L., Law, A. H., Li, J. C., & Lau, A. S. (2011). Isolation and identiﬁcation of
anti-inﬂammatory constituents from Ligusticum chuanxiong and their underlying
mechanisms of action on microglia. Neuropharmacology 60, 823–831.
Oyadomari, S., & Mori, M. (2004). Roles of CHOP/GADD153 in endoplasmic reticulum
stress. Cell Death Differ 11, 381–389.
Oyadomari, S., Araki, E., & Mori, M. (2002). Endoplasmic reticulum stress-mediated
apoptosis in pancreatic beta-cells. Apoptosis 7, 335–345.
Penugonda, S., Mare, S., Goldstein, G., Banks, W. A., & Ercal, N. (2005). Effects of N-
acetylcysteine amide (NACA), a novel thiol antioxidant against glutamate-induced
cytotoxicity in neuronal cell line PC12. Brain Res 1056, 132–138.
Pereira, C. F., & Oliveira, C. R. (2000). Oxidative glutamate toxicity involves mitochondrial
dysfunction and perturbation of intracellular Ca2+ homeostasis. Neurosci Res 37,
227–236.
Ploeger, B., Mensinga, T., Sips, A., Seinen, W., Meulenbelt, J., & DeJongh, J. (2001). The
pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmaco-
kinetic modeling. Drug Metab Rev 33, 125–147.
Porter, N., Herman, J. P., & Landﬁeld, P. W. (2001). Mechanisms of glucocorticoid actions
in stress and brain aging. In B. S. McEwen (Ed.), Handbook of physiology: Coping with
the environment (pp. 293–309). Oxford: Oxford University Press.
Saito, S., Kobayashi, T., Osawa, T., & Kato, S. (2010). Effectiveness of Japanese herbal med-
icine yokukansan for alleviating psychiatric symptoms after traumatic brain injury.
Psychogeriatrics 10, 45–48.
Sapolsky, R. M., Krey, L. C., & McEwen, B. S. (1986). The neuroendocrinology of stress and
aging: The glucocorticoid cascade hypothesis. Endocr Rev 7, 284–301.
Schubert, D., Kimura, H., & Maher, P. (1992). Growth factors and vitamin E modify
neuronal glutamate toxicity. Proc Natl Acad Sci U S A 89, 8264–8267.
Sekiguchi, K., Imamura, S., Yamaguchi, T., Tabuchi, M., Kanno, H., Terawaki, K., et al.
(2011). Effects of yokukansan and donepezil on learning disturbance and aggressive-
ness induced by intracerebroventricular injection of amyloid β protein in mice.
Phytother Res 25, 501–507.
Sekiguchi, K., Kanno, H., Yamaguchi, T., Ikarashi, Y., & Kase, Y. (2012). Ameliorative effect of
yokukansan onvacuous chewingmovement inhaloperidol-induced rat tardive dyski-
nesia model and involvement of glutamatergic system. Brain Res Bull 89, 151–158.
Sekiguchi, K., Yamaguchi, T., Tabuchi, M., Ikarashi, Y., & Kase, Y. (2009). Effects of
yokukansan, a traditional Japanese medicine, on aggressiveness induced by
intracerebro-ventricular injection of amyloid β protein into mice. Phytother Res 23,
1175–1181.
Seo, M. J., Kim, S. J., Kang, T. H., Rim, H. K., Jeong, H. J., Um, J. Y., et al. (2011). The regulatory
mechanism of beta-eudesmol is through the suppression of caspase-1 activation in
mast cell-mediated inﬂammatory response. Immunopharmacol Immunotoxicol 33,
178–185.
Shimizu, S., Tanaka, T., Takeda, T., Tohyama,M., &Miyata, S. (2015a). The kampomedicine
yokukansan decreases microRNA-18 expression and recovers glucocorticoid
receptors protein expression in the hypothalamus of stressed mice. Biomed Res Int
2015, 797280.
Shimizu, S., Tanaka, T., Tohyama, M., & Miyata, S. (2015b). Yokukansan normalizes
glucocorticoid receptor protein expression in oligodendrocytes of the corpus
callosum by regulating microRNA-124a expression after stress exposure. Brain Res
Bull 114, 49–55.
95Y. Ikarashi, K. Mizoguchi / Pharmacology & Therapeutics 166 (2016) 84–95Shoji, H., & Mizoguchi, K. (2013). Brain region-speciﬁc reduction in c-Fos expression
associated with an anxiolytic effect of yokukansan in rats. J Ethnopharmacol 149,
93–102.
Sidrauski, C., Chapman, R., & Walter, P. (1998). The unfolded protein response: An
intracellular signaling pathway with many surprising features. Trends Cell Biol 8,
245–249.
Song, Y., Qu, R., Zhu, S., Zhang, R., & Ma, S. (2012). Rhynchophylline attenuates LPS-
induced pro-inﬂammatory responses through down-regulation of MAPK/NF-
kappaB signaling pathways in primary microglia. Phytother Res 26, 1528–1533.
Sun, J., Ren, X., Med,W. Q., Yuan, D., & Simpkins, J. W. (2016). Geissoschizinemethyl ether
protects oxidative stress-mediated cytotoxicity in neurons through the ‘neuronal
Warburg effect’. J Ethnopharmacol 187, 249–258.
Suzuki, Y., Mitsuhata, H., Yuzurihara, M., & Kase, Y. (2012). Antiallodynic effect of herbal
medicine yokukansan on peripheral neuropathy in rats with chronic constriction
injury. Evid Based Complement Alternat Med 2012, 953459.
Tabuchi, M., Imamura, S., Kawakami, Z., Ikarashi, Y., & Kase, Y. (2012). The blood–brain
barrier permeability of 18β-glycyrrhetinic acid, a major metabolite of glycyrrhizin
in Glycyrrhiza root, a constitutent of the traditional Japanese medicine yokukansan.
Cell Mol Neurobiol 32, 1139–1146.
Tabuchi, M., Yamaguchi, T., Iizuka, S., Imamura, S., Ikarashi, Y., & Kase, Y. (2009). Amelio-
rative effects of yokukansan, a traditional Japanese medicine, on learning and non-
cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease. J
Ethnopharmacol 122, 157–162.
Takeda, S., Ishihara, K., Wakui, Y., Amagaya, S., Maruno,M., Akao, T., et al. (1996). Bioavail-
ability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats;
relevance to the intestinal bacterial hydrolysis. J Pharm Pharmacol 48, 902–905.
Takeda, A., Itoh, H., Tamano, H., Yuzurihara, M., & Oku, N. (2008a). Suppressive effect of
yokukansan on excessive release of glutamate and aspartate in the hippocampus of
zinc-deﬁcient rats. Nutr Neurosci 11, 41–46.
Takeda, A., Iwaki, H., Ide, K., Tamano, H., & Oku, N. (2012). Therapeutic effect of
yokukansan on social isolation-induced aggressive behavior of zinc-deﬁcient and
pair-fed mice. Brain Res Bull 87, 551–555.
Takeda, A., Tamano, H., Itoh, H., & Oku, N. (2008b). Attenuation of abnormal glutamate
release in zinc deﬁciency by zinc and yokukansan. Neurochem Int 53, 230–235.
Tamano, H., Kan, F., Oku, N., & Takeda, A. (2010). Ameliorative effect of yokukansan on so-
cial isolation-induced aggressive behavior of zinc-deﬁcient young mice. Brain Res Bull
83, 351–355.
Tamano, H., Yusuke, E., Ide, K., & Takeda, A. (2016). Inﬂuences of
Yokukansankachimpihange on aggressive behavior of zinc-deﬁcient mice and actions
of the ingredients on excessive neural exocytosis in the hippocampus of zinc-deﬁ-
cient rats. Exp Anim (in press).
Tanaka, Y., & Mizoguchi, K. (2009). Inﬂuence of aging on chondroitin sulfate proteoglycan
expression and neural stem/progenitor cells in rat brain and improving effects of a
herbal medicine, yokukansan. Neuroscience 164, 1224–1234.
Tanji, H., Ootsuki, M., Matsui, T., Maruyama, M., Nemoto, M., Tomita, N., et al. (2005).
Dementia caregiver's burdens and use of public services. Geriatr Gerontol Int 5, 94–98.
Tateno, M., Ukai, W., Ono, T., Saito, S., Hashimoto, E., & Saito, T. (2008). Neuroprotective
effects of Yi-Gan San against beta amyloid-induced cytotoxicity on rat cortical neu-
rons. Prog Neuropsychopharmacol Biol Psychiatry 32, 1704–1707.
Terawaki, K., Ikarashi, Y., Sekiguchi, K., Nakai, Y., & Kase, Y. (2010). Partial agonistic effect
of yokukansan on human recombinant serotonin 1A receptors expressed in the
membranes of Chinese hamster ovary cells. J Ethnopharmacol 127, 306–312.
Tirasophon, W.,Welihinda, A. A., & Kaufman, R. J. (1998). A stress response pathway from
the endoplasmic reticulum to the nucleus requires a novel bifunctional protein
kinase/endoribonuclease (Ire1p) in mammalian cells. Genes Dev 12, 1812–1824.
Tsuji, M., Inanami, O., & Kuwabara, M. (2001). Induction of neurite outgrowth in PC12
cells by alpha-phenyl-N-tert-butylnitron through activation of protein kinase C and
the Ras-extracellular signal-regulated kinase pathway. J Biol Chem 276, 32779–32785.Tsuji, M., Takeuchi, T., Miyagawa, K., Ishii, D., Imai, T., Takeda, K., et al. (2014).
Yokukansan, a traditional Japanese herbal medicine, alleviates the emotional
abnormality induced by maladaptation to stress in mice. Phytomedicine 21, 363–371.
Uchida, N., Takasaki, K., Sakata, Y., Nogami, A., Oishi, H., Watanabe, T., et al. (2013).
Cholinergic involvement and synaptic dynamin 1 expression in yokukansan-
mediated improvement of spatial memory in a rat model of early Alzheimer's disease.
Phytother Res 27, 966–972.
Ueda, T., Ugawa, S., Ishida, Y., & Shimada, S. (2011). Geissoschizine methyl ester has third-
generation antipsychotic-like actions at the dopamine and serotonin receptors. Eur J
Pharmacol 671, 79–86.
Ueki, T., Ikarashi, Y., Kawakami, Z., Mizoguchi, K., & Kase, Y. (2014). Promotive effects of
yokukansan, a traditional Japanese medicine, on proliferation and differentiation of
cultured mouse cortical oligodendrocytes. Pharmacol Pharm 5, 670–680.
Ueki, T., Mizoguchi, K., Yamaguchi, T., Nishi, A., Ikarashi, Y., Hattori, T., et al. (2015a).
Yokukansan increases 5-HT1A receptors in the prefrontal cortex and enhances 5-
HT1A receptor agonist-induced behavioral responses in socially isolated mice. Evid
Based Complement Alternat Med 2015, 726471.
Ueki, T., Mizoguchi, K., Yamaguchi, T., Nishi, A., Sekiguchi, K., Ikarashi, Y., et al. (2015b).
Yokukansan, a traditional Japanese medicine, decreases head-twitch behaviors and
serotonin 2A receptors in the prefrontal cortex of isolation-stressed mice. J
Ethnopharmacol 166, 23–30.
Ueki, T., Nishi, A., Imamura, S., Kanno, H., Mizoguchi, K., Sekiguchi, K., et al. (2013). Effects
of geissoschizine methyl ether, an indole alkaloid in Uncaria hook, a constituent of
yokukansan, on human recombinant serotonin 7 receptor. Cell Mol Neurobiol 33,
129–135.
Vaudry, D., Stork, P. J., Lazarovici, P., & Eiden, L. E. (2002). Signaling pathways for PC12 cell
differentiation: making the right connections. Science 296, 1648–1649.
Vazhappilly, R., Wee, K. S., Sucher, N. J., & Low, C. M. (2010). A non-muscle myosin II
motor links NR1 to retrograde trafﬁcking and proteasomal degradation in PC12
cells. Neurochem Int 56, 569–576.
Vreugdenhil, E., Verissimo, C. S., Mariman, R., Kamphorst, J. T., Barbosa, J. S., Zweers, T.,
et al. (2009). MicroRNA 18 and 124a down-regulate the glucocorticoid receptor:
implications for glucocorticoid responsiveness in the brain. Endocrinology 150,
2220–2228.
Wang, Z., Kurosaki, Y., Nakayama, T., & Kimura, T. (1994). Mechanism of gastrointestinal
absorption of glycyrrhizin in rats. Biol Pharm Bull 17, 1399–1403.
Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., et al.
(2005). Risk of death in elderly users of conventional vs. atypical antipsychotic
medications. N Engl J Med 353, 2335–2341.
Wang, Y., Stricker, H. M., Gou, D., & Liu, L. (2007). MicroRNA: past and present. Front Biosci
12, 2316–2329.
Wieland, S., Fischette, C. T., & Lucki, I. (1993). Effect of chronic treatments with
tandospirone and imipramine on serotonin-mediated behavioral responses and
monoamine receptors. Neuropharmacology 32, 561–573.
Yamaguchi, T., Tsujimatsu, A., Kumamoto, H., Izumi, T., Ohmura, Y., Yoshida, T., et al.
(2012). Anxiolytic effects of yokukansan, a traditional Japanese medicine, via
serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aver-
sive stress. J Ethnopharmacol 143, 533–539 (2012).
Yuan, R., & Lin, Y. (2000). Traditional Chinese medicine: An approach to scientiﬁc proof
and clinical validation. Pharmacol Ther 86, 191–198.
Yuan, D., Ma, B., Yang, J. Y., Xie, Y. Y.,Wang, L., Zhang, L. J., et al. (2009). Anti-inﬂammatory
effects of rhynchophylline and isorhynchophylline in mouse N9 microglial cells and
the molecular mechanism. Int Immunopharmacol 9, 1549–1554.
Zhu, M. Y., Piletz, J. E., Halaris, A., & Regunathan, S. (2003). Effect of agmatine against cell
death induced by NMDA and glutamate in neurons and PC12 cells. Cell Mol Neurobiol
23, 865–872.
